Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans T Chung

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 3, 2018
Quality of life changes after stereotactic ablative radiotherapy for liver metastases: A prospective cohort analysisJoelle Helou, Isabelle Thibault, William Chu, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 28, 2012
The effect of radiation technique and bladder filling on the acute toxicity of pelvic radiotherapy for localized high risk prostate cancerSuneil Jain, D Andrew Loblaw, Gerard C Morton, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 29, 2021
Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trialRachel M Glicksman, Andrew Loblaw, Gerard Morton, et al.
Translational Oncology|March 10, 2015
Quantitative ultrasound spectroscopic imaging for characterization of disease extent in prostate cancer patientsAli Sadeghi-Naini, Ervis Sofroni, Naum Papanicolau, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 15, 2024
Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy: A 9-year updateJohn M Hudson, Andrew Loblaw, Merrylee McGuffin, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 11, 2025
Updated results of MR-assisted focal salvage HDR prostate brachytherapy: a prospective studyGregory Paulin, Gerard Morton, Andrew Loblaw, et al.
International Journal of Radiation Oncology, Biology, Physics|October 12, 2021
Gantry-Based 5-Fraction Elective Nodal Irradiation in Unfavorable-Risk Prostate Cancer: Outcomes From 2 Prospective Studies Comparing SABR Boost With MR Dose-Painted HDR Brachytherapy BoostHima Bindu Musunuru, Patrick Cheung, Danny Vesprini, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 5, 2021
Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): Efficacy, toxicity and quality of lifeHima Bindu Musunuru, Patrick Cheung, Danny Vesprini, et al.
Clinical and Translational Radiation Oncology|September 25, 2024
Elective pelvic nodal irradiation in the setting of ultrahypofractionated versus moderately hypofractionated and conventionally fractionated radiotherapy for prostate cancer: Outcomes from 3 prospective clinical trialsRachel M Glicksman, Andrew Loblaw, Gerard Morton, et al.
International Journal of Radiation Oncology, Biology, Physics|November 18, 2023
Randomized Trial of Concomitant Hypofractionated Intensity Modulated Radiation Therapy Boost Versus Conventionally Fractionated Intensity Modulated Radiation Therapy Boost for Localized High-Risk Prostate Cancer (pHART2-RCT)Rachel M Glicksman, Andrew Loblaw, Gerard Morton, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 3, 2018
Quality of life changes after stereotactic ablative radiotherapy for liver metastases: A prospective cohort analysisJoelle Helou, Isabelle Thibault, William Chu, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 28, 2012
The effect of radiation technique and bladder filling on the acute toxicity of pelvic radiotherapy for localized high risk prostate cancerSuneil Jain, D Andrew Loblaw, Gerard C Morton, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 29, 2021
Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trialRachel M Glicksman, Andrew Loblaw, Gerard Morton, et al.
Translational Oncology|March 10, 2015
Quantitative ultrasound spectroscopic imaging for characterization of disease extent in prostate cancer patientsAli Sadeghi-Naini, Ervis Sofroni, Naum Papanicolau, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 15, 2024
Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy: A 9-year updateJohn M Hudson, Andrew Loblaw, Merrylee McGuffin, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 11, 2025
Updated results of MR-assisted focal salvage HDR prostate brachytherapy: a prospective studyGregory Paulin, Gerard Morton, Andrew Loblaw, et al.
International Journal of Radiation Oncology, Biology, Physics|October 12, 2021
Gantry-Based 5-Fraction Elective Nodal Irradiation in Unfavorable-Risk Prostate Cancer: Outcomes From 2 Prospective Studies Comparing SABR Boost With MR Dose-Painted HDR Brachytherapy BoostHima Bindu Musunuru, Patrick Cheung, Danny Vesprini, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 5, 2021
Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): Efficacy, toxicity and quality of lifeHima Bindu Musunuru, Patrick Cheung, Danny Vesprini, et al.
Clinical and Translational Radiation Oncology|September 25, 2024
Elective pelvic nodal irradiation in the setting of ultrahypofractionated versus moderately hypofractionated and conventionally fractionated radiotherapy for prostate cancer: Outcomes from 3 prospective clinical trialsRachel M Glicksman, Andrew Loblaw, Gerard Morton, et al.
International Journal of Radiation Oncology, Biology, Physics|November 18, 2023
Randomized Trial of Concomitant Hypofractionated Intensity Modulated Radiation Therapy Boost Versus Conventionally Fractionated Intensity Modulated Radiation Therapy Boost for Localized High-Risk Prostate Cancer (pHART2-RCT)Rachel M Glicksman, Andrew Loblaw, Gerard Morton, et al.
Pageof 6